Streetbeat News

PROK

ProKidney Corp.

https://www.prokidney.com

Industry

Biotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

ProKidney (NASDAQ:PROK) reported Q2 EPS of $(0.16), beating the $(0.17) estimate. The company ended the quarter with $431.5M in cash and equivalents, despite a 14.29% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:17 am

The article highlights notable insider trades in three companies: PBF Energy, Citi Trends, and ProKidney. Insider purchases often indicate confidence in the company's prospects. PBF Energy's 10% owner acquired $30.83 million worth of shares, Citi Trends' 10% owner bought $2.07 million worth of shares, and ProKidney's 10% owner purchased $20 million worth of shares.

Portfolio Pulse from Avi Kapoor

June 26, 2024 | 12:37 pm

ProKidney has announced an upsized public offering of $130 million, involving 53,719,009 Class A ordinary shares priced at $2.42 per share. The offering is expected to close around June 13, 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 6:25 am

Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply by 18.4% after the company announced a $15 million underwritten public offering. Other notable stock movements include Trio Petroleum Corp. (NYSE:TPET) jumping 88.2% after completing its first two exploratory wells, and Airship AI Holdings, Inc. (NASDAQ:AISP) climbing 32.5% following a contract award from the Department of Justice.

Portfolio Pulse from Avi Kapoor

June 11, 2024 | 5:54 pm

The article highlights the intraday movements of 12 healthcare stocks on Tuesday. Notable gainers include Elutia, Trinity Biotech, and Akari Therapeutics, while significant losers include ProKidney, BioSig Technologies, and Inspire Veterinary.

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 4:31 pm

Calavo Growers, Inc. (NASDAQ:CVGW) shares surged 11.6% in pre-market trading after reporting strong Q2 financial results with a 16.5% increase in net sales and a significant rise in adjusted net income. Other notable pre-market movers include ShiftPixy, Inc. (NASDAQ:PIXY), Nauticus Robotics, Inc. (NASDAQ:KITT), and Target Hospitality Corp. (NASDAQ:TH), among others.

Portfolio Pulse from Avi Kapoor

June 11, 2024 | 12:39 pm

The article highlights the pre-market movements of 12 health care stocks on Tuesday. Notable gainers include Viracta Therapeutics (VIRX), Purple Biotech (PPBT), Akanda (AKAN), Viridian Therapeutics (VRDN), IGC Pharma (IGC), and OpGen (OPGN). Significant losers include ProKidney (PROK), Nuwellis (NUWE), Virax Biolabs Group (VRAX), SILO Pharma (SILO), iSpecimen (ISPC), and FibroBiologics (FBLG).

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 12:06 pm

The article highlights the performance of various health care stocks during Monday's after-market session. Notable gainers include Entero Therapeutics (NASDAQ:ENTO), Akanda (NASDAQ:AKAN), and LifeMD (NASDAQ:LFMD). Significant losers include Vicarious Surgical (NYSE:RBOT), ProKidney (NASDAQ:PROK), and Ocean Biomedical (NASDAQ:OCEA).

Portfolio Pulse from Benzinga Insights

June 10, 2024 | 8:31 pm

ProKidney Corp. has announced a $125 million public offering and a concurrent registered direct offering of Class A ordinary shares. Additionally, underwriters have a 30-day option to purchase up to an additional 15% of the shares.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 8:16 pm

ProKidney shares are trading lower following an operational update and progress report on European and U.S. clinical trials for its CKD therapy, rilparencel. Jefferies maintained a Buy rating but lowered the price target from $15 to $6.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 7:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.